| pathology | Benefit (demonstrated or suggested) and harm | | | |
|---|
| acute coronary syndrome | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| STAI, 1990 | vs control | Vasc events 0.52 [0.32; 0.83] Non-fatal MI 0.54 [0.30; 0.98] cardiovascular events 0.52 [0.32; 0.83] | | Major bleeds NaN [NaN; NaN] Vasc deaths 0.54 [0.23; 1.24] Non-fatal stroke 0.00 [0.00; NaN] Non vasc deaths NaN [NaN; NaN] | | Florida UA | vs control | | | Vasc events 1.00 [0.17; 5.98] Major bleeds NaN [NaN; NaN] Vasc deaths NaN [NaN; NaN] Non-fatal stroke NaN [NaN; NaN] Non-fatal MI 1.00 [0.17; 5.98] Non vasc deaths NaN [NaN; NaN] cardiovascular events 1.00 [0.17; 5.98] | | Knudsen-A, 1985 | vs control | | | vascular death NaN [NaN; NaN] non fatla stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] vascular events NaN [NaN; NaN] non vascular death NaN [NaN; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| STAI, 1990 | ticlopidine 250 mg b.i.d (n=314) vs. untreated control (n=338) | patients with unstable angina <=48hrs from the pain onset | single blind Sample size: 314/338 Primary endpoint: FU duration: 6m | | Florida UA | Ticlopidine 500mg/d (n=12) vs. (n=12) | | Sample size: 12/12 Primary endpoint: FU duration: 14d | | Knudsen-A, 1985 | ticlopidine 500mg/d (n=24) vs. placebo (n=19) | patients with AMI | double blind Parallel groups Sample size: 24/19 Primary endpoint: FU duration: 3m |
|
| acute myocardial infarction | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Knudsen-A, 1985 | vs control | | | vascular death NaN [NaN; NaN] non fatla stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] vascular events NaN [NaN; NaN] non vascular death NaN [NaN; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| Knudsen-A, 1985 | ticlopidine 500mg/d (n=24) vs. placebo (n=19) | patients with AMI | double blind Parallel groups Sample size: 24/19 Primary endpoint: FU duration: 3m |
|
| CABG surgery | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Liège-I, 1984 | vs control | | | vascular death 0.00 [0.00; NaN] Non fatal stroke 0.00 [0.00; NaN] non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event 0.00 [0.00; NaN] | | Liège-II, 1987 | vs control | | | vascular death 1.98 [0.18; 21.41] Non fatal stroke 0.00 [0.00; NaN] non fatal MI 0.33 [0.03; 3.11] non vascular death 0.00 [0.00; NaN] vascular event 0.49 [0.13; 1.91] | | vs control | | | | | vs control | | | | | vs control | | | | | vs control | | | |
| Trial | Treatments | Patients | Method |
|---|
| Liège-I, 1984 | ticlopidine 250 mg twice daily (n=75) vs. placebo (n=75) | patients undergoing aortocoronary bypass graft procedures | double blind Sample size: 75/75 Primary endpoint: FU duration: 3m | | Liège-II, 1987 | ticlopidine 250 mg twice daily (n=88) vs. placebo (n=87) | patients undergoing venous coronary artery bypass grafting | double blind Sample size: 88/87 Primary endpoint: FU duration: 12m | | Zurich, 1982 | ticlopidine 500 (NC) (n=50) vs. (n=50) | | Sample size: 50/50 Primary endpoint: FU duration: 3m | | Knudsen-B, 1983 | ticlopidine 500 (n=9) vs. (n=10) | | Sample size: 9/10 Primary endpoint: FU duration: 6m | | Romeo, 1983 | ticlopidine 500 (n=20) vs. (n=20) | | Sample size: 20/20 Primary endpoint: FU duration: 3m (12m) | | Kohn, 1990 | ticlopidine 500 (n=21) vs. (n=24) | | Sample size: 21/24 Primary endpoint: FU duration: 14d |
|
| cardiovascular prevention | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | Berglund, 1985 | vs placebo | | | vascular death NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event NaN [NaN; NaN] | | Birmingham-A, 1979 | vs placebo | | | All cause mortality NaN [NaN; NaN] CV death NaN [NaN; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] | | London diabetes, 1983 | vs placebo | | | All cause mortality 1.05 [0.07; 16.24] CV death 1.05 [0.07; 16.24] non fatal MI NaN [NaN; NaN] CV events (fatal and non fatal) 0.53 [0.05; 5.57] | | TIMAD, 1984 | vs placebo | | | All cause mortality 0.73 [0.17; 3.24] CV death 0.49 [0.04; 5.35] non fatal MI 0.33 [0.03; 3.84] CV events (fatal and non fatal) 0.56 [0.17; 1.88] | | BTRS, 1992 | vs placebo | | | All cause mortality NaN [NaN; NaN] CV death NaN [NaN; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] | | Nyberg, 1984 | vs placebo | | | All cause mortality ∞ [NaN; ∞] CV death ∞ [NaN; ∞] non fatal MI NaN [NaN; NaN] CV events (fatal and non fatal) ∞ [NaN; ∞] |
| Trial | Treatments | Patients | Method |
|---|
| EMATAP, 1993 | Ticlopidine 500 mg/j (n=304) vs. Placebo (n=311) | AOMI stade non précisé | double blind Parallel groups Sample size: 304/311 Primary endpoint: Mortalité subite, IDM, AVC, intervention chirurgicale liée à une aggravation clinique FU duration: | | Katsumara, 1982 | Ticlopidine 500 mg/j (n=93) vs. Placebo (n=100) | patients with ischemic ulcers due to chronic arterial occlusion | double blind Parallel groups Sample size: 93/100 Primary endpoint: Taille / cicatrisation des ulcères FU duration: 6 semaines | | Aukland, 1982 | Ticlopidine 500 mg/j (n=33) vs. Placebo (n=32) | men with atherosclerotic intermittent claudication and haemorheological abnormalities | double blind Parallel groups Sample size: 33/32 Primary endpoint: Périmètre de marche, pressionsystolique à la cheville FU duration: 1 y | | Stiegler, 1984 | Ticlopidine 500 mg/j (n=57) vs. Placebo (n=57) | AOMI stade II | double blind Parallel groups Sample size: 57/57 Primary endpoint: Score de progression de l’athérosclérose FU duration: | | Ellis, 1986 | Ticlopidine 500 mg/j (n=100) vs. Placebo (n=103) | AOMI stade II | double blind Parallel groups Sample size: 100/103 Primary endpoint: Périmètre de marche FU duration: 6 months | | Cloarec, 1986 | Ticlopidine 500 mg/j (n=66) vs. Placebo (n=66) | AOMI stade non précisé | double blind Parallel groups Sample size: 66/66 Primary endpoint: Périmètre de marche FU duration: 1 y | | Arcan, 1988 | Ticlopidine 500 mg/j (n=83) vs. Placebo (n=86) | patients with chronic intermittent claudication due to obstructive peripheral vascular disease (stade II) | double blind Parallel groups Sample size: 83/86 Primary endpoint: Périmètre de marche FU duration: 6 months randomisation centralisée | | Balsano, 1989 | Ticlopidine 500 mg/j (n=76) vs. Placebo (n=75) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 76/75 Primary endpoint: Périmètre de marche FU duration: 21 months | | STIMS, 1990 | Ticlopidine 500 mg/j (n=346) vs. Placebo (n=341) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 346/341 Primary endpoint: IDM, AVC, AIT FU duration: 5.6 y | | Hurlow, 1980 | Ticlopidine : 100 -500 mg / jour pendant 2 mois. (n=30) vs. Placebo (n=30) | Données non disponibles | double blind Parallel groups Sample size: 30/30 Primary endpoint: FU duration: | | Krause, 1980 | Ticlopidine : 500 mg pendant 4 mois (n=19) vs. Placebo (n=19) | Données non disponibles | double blind Parallel groups Sample size: 19/19 Primary endpoint: FU duration: | | Berglund, 1985 | ticlopidine 500 mg daily (n=21) vs. placebo (n=17) | middle-aged men with stable incapacitating angina pectoris | double blind parallel groups Sample size: 21/17 Primary endpoint: not defined FU duration: 2m | | Birmingham-A, 1979 | ticlopidine 100, 250, 500 mg (n=20) vs. (n=8) | | Parallel groups Sample size: 20/8 Primary endpoint: FU duration: 2 months | | London diabetes, 1983 | ticlopidine 500mg (n=38) vs. (n=40) | | Parallel groups Sample size: 38/40 Primary endpoint: FU duration: 12 months | | TIMAD, 1984 | ticlopidine 500mg (n=220) vs. (n=215) | | Parallel groups Sample size: 220/215 Primary endpoint: FU duration: 32m | | BTRS, 1992 | ticlopidine 500mg/d (n=49) vs. placebo (n=51) | insulin-treated diabetics with background retinopathy | double blind Parallel groups Sample size: 49/51 Primary endpoint: evolution of retinopathy FU duration: 48 months | | Nyberg, 1984 | ticlopidine 500mg daily (n=12) vs. placebo (n=11) | insulin dependent diabetes complicated by nephropathy | double blind Parallel groups Sample size: 12/11 Primary endpoint: FU duration: 12 months |
|
| coronary artery disease | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Berglund, 1985 | vs placebo | | | vascular death NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event NaN [NaN; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| Berglund, 1985 | ticlopidine 500 mg daily (n=21) vs. placebo (n=17) | middle-aged men with stable incapacitating angina pectoris | double blind parallel groups Sample size: 21/17 Primary endpoint: not defined FU duration: 2m |
|
| diabetes type 2 | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Birmingham-A, 1979 | vs placebo | | | All cause mortality NaN [NaN; NaN] CV death NaN [NaN; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] | | London diabetes, 1983 | vs placebo | | | All cause mortality 1.05 [0.07; 16.24] CV death 1.05 [0.07; 16.24] non fatal MI NaN [NaN; NaN] CV events (fatal and non fatal) 0.53 [0.05; 5.57] | | TIMAD, 1984 | vs placebo | | | All cause mortality 0.73 [0.17; 3.24] CV death 0.49 [0.04; 5.35] non fatal MI 0.33 [0.03; 3.84] CV events (fatal and non fatal) 0.56 [0.17; 1.88] | | BTRS, 1992 | vs placebo | | | All cause mortality NaN [NaN; NaN] CV death NaN [NaN; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] | | Nyberg, 1984 | vs placebo | | | All cause mortality ∞ [NaN; ∞] CV death ∞ [NaN; ∞] non fatal MI NaN [NaN; NaN] CV events (fatal and non fatal) ∞ [NaN; ∞] |
| Trial | Treatments | Patients | Method |
|---|
| Birmingham-A, 1979 | ticlopidine 100, 250, 500 mg (n=20) vs. (n=8) | | Parallel groups Sample size: 20/8 Primary endpoint: FU duration: 2 months | | London diabetes, 1983 | ticlopidine 500mg (n=38) vs. (n=40) | | Parallel groups Sample size: 38/40 Primary endpoint: FU duration: 12 months | | TIMAD, 1984 | ticlopidine 500mg (n=220) vs. (n=215) | | Parallel groups Sample size: 220/215 Primary endpoint: FU duration: 32m | | BTRS, 1992 | ticlopidine 500mg/d (n=49) vs. placebo (n=51) | insulin-treated diabetics with background retinopathy | double blind Parallel groups Sample size: 49/51 Primary endpoint: evolution of retinopathy FU duration: 48 months | | Nyberg, 1984 | ticlopidine 500mg daily (n=12) vs. placebo (n=11) | insulin dependent diabetes complicated by nephropathy | double blind Parallel groups Sample size: 12/11 Primary endpoint: FU duration: 12 months |
|
| percutaneous coronary intervention | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| TACT, 1990 | vs aspirin | | | Non fatal MI 0.49 [0.17; 1.40] vascular deaths ∞ [NaN; ∞] Non fatal stroke 0.98 [0.06; 15.50] Non fatal MI 0.49 [0.17; 1.40] vascular events 0.62 [0.25; 1.57] non vascular death NaN [NaN; NaN] | | FANTASTIC, 1998 | vs aspirin | | | MACE 0.70 [0.36; 1.36] | | ISAR, 1996 | vs aspirin | MACE 0.25 [0.09; 0.75] | | | | Foussas, 2000 | vs aspirin | MACE 0.31 [0.15; 0.63] | | | | MATTIS, 1998 | vs aspirin | | | MACE 0.51 [0.25; 1.07] | | STARS (vs coumadin+asp), 1998 | vs aspirin | MACE 0.20 [0.06; 0.69] | | | | STARS (vs aspirin), 1998 | vs aspirin | MACE 0.15 [0.05; 0.51] | | | | Hall, 1996 | vs aspirin | | | MACE 1.98 [0.24; 16.40] | | vs aspirin | | | |
| Trial | Treatments | Patients | Method |
|---|
| TACT, 1990 | ticlopidine 500, aspirin 650 + D225 (n=177) vs. (n=173) | | Parallel groups Sample size: 177/173 Primary endpoint: FU duration: 6m | | FANTASTIC, 1998 | Ticlopidine 250 mg BID 6 wks Aspirin 100–325 mg qD (n=243) vs. Coumadin INR† 2.5–3.0 6 wks Aspirin 100–325 mg qD/pj (n=230) | | Sample size: 243/230 Primary endpoint: FU duration: | | ISAR, 1996 | Ticlopidine 250 mg BID 4 wks Aspirin 100 mg BIDage/pj (n=257) vs. Coumadin INR 3.5–4.5 4 wks Aspirin 100 mg BID (n=260) | | Sample size: 257/260 Primary endpoint: FU duration: | | Foussas, 2000 | Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD (n=203) vs. Coumadin INR 2–3 x4 wks Aspirin 325 mg qDg BID (n=201) | | Sample size: 203/201 Primary endpoint: FU duration: | | MATTIS, 1998 | Ticlopidine 250 mg BID 30 days Aspirin 250 mg qD (n=177) vs. Coumadin INR 2.5–3.0 x30 days Aspirin 250 mg qDg qD/pj (n=173) | | Sample size: 177/173 Primary endpoint: FU duration: | | STARS (vs coumadin+asp), 1998 | Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD (n=546) vs. Coumadin INR 2–2.5 x4 wks Aspirin 325 mg qDBID (n=550) | | Sample size: 546/550 Primary endpoint: FU duration: | | STARS (vs aspirin), 1998 | Ticlopidine 250 mg BID 4 wks Aspirin 325 mg qDDage/pj (n=546) vs. Aspirin 325 mg qD (n=557) | | Sample size: 546/557 Primary endpoint: FU duration: | | Hall, 1996 | Ticlopidine 250 mg BID 1 mo Aspirin 325 mg qD 5 days (n=13) vs. Aspirin 325 mg qD (n=103) | | Sample size: 13/103 Primary endpoint: FU duration: | | White (ticlopidine), 1991 | ticlopidine 500, aspirin 650 + D225 (n=-9) vs. placebo (n=254)
|
| Parallel groups Sample size: -9/254 Primary endpoint: FU duration: 6m
|
|
| peripheral vascular diseases | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | | | vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| EMATAP, 1993 | Ticlopidine 500 mg/j (n=304) vs. Placebo (n=311) | AOMI stade non précisé | double blind Parallel groups Sample size: 304/311 Primary endpoint: Mortalité subite, IDM, AVC, intervention chirurgicale liée à une aggravation clinique FU duration: | | Katsumara, 1982 | Ticlopidine 500 mg/j (n=93) vs. Placebo (n=100) | patients with ischemic ulcers due to chronic arterial occlusion | double blind Parallel groups Sample size: 93/100 Primary endpoint: Taille / cicatrisation des ulcères FU duration: 6 semaines | | Aukland, 1982 | Ticlopidine 500 mg/j (n=33) vs. Placebo (n=32) | men with atherosclerotic intermittent claudication and haemorheological abnormalities | double blind Parallel groups Sample size: 33/32 Primary endpoint: Périmètre de marche, pressionsystolique à la cheville FU duration: 1 y | | Stiegler, 1984 | Ticlopidine 500 mg/j (n=57) vs. Placebo (n=57) | AOMI stade II | double blind Parallel groups Sample size: 57/57 Primary endpoint: Score de progression de l’athérosclérose FU duration: | | Ellis, 1986 | Ticlopidine 500 mg/j (n=100) vs. Placebo (n=103) | AOMI stade II | double blind Parallel groups Sample size: 100/103 Primary endpoint: Périmètre de marche FU duration: 6 months | | Cloarec, 1986 | Ticlopidine 500 mg/j (n=66) vs. Placebo (n=66) | AOMI stade non précisé | double blind Parallel groups Sample size: 66/66 Primary endpoint: Périmètre de marche FU duration: 1 y | | Arcan, 1988 | Ticlopidine 500 mg/j (n=83) vs. Placebo (n=86) | patients with chronic intermittent claudication due to obstructive peripheral vascular disease (stade II) | double blind Parallel groups Sample size: 83/86 Primary endpoint: Périmètre de marche FU duration: 6 months randomisation centralisée | | Balsano, 1989 | Ticlopidine 500 mg/j (n=76) vs. Placebo (n=75) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 76/75 Primary endpoint: Périmètre de marche FU duration: 21 months | | STIMS, 1990 | Ticlopidine 500 mg/j (n=346) vs. Placebo (n=341) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 346/341 Primary endpoint: IDM, AVC, AIT FU duration: 5.6 y | | Hurlow, 1980 | Ticlopidine : 100 -500 mg / jour pendant 2 mois. (n=30) vs. Placebo (n=30) | Données non disponibles | double blind Parallel groups Sample size: 30/30 Primary endpoint: FU duration: | | Krause, 1980 | Ticlopidine : 500 mg pendant 4 mois (n=19) vs. Placebo (n=19) | Données non disponibles | double blind Parallel groups Sample size: 19/19 Primary endpoint: FU duration: | | Becquemin, 1997 | Ticlopidine (Ticlid, sanofi)
250 mg*2 /j (n=122) vs. placebo (n=121) | Patients au stade II à IV Pas de différences dans les caractéristiques des patients sauf pour les "anastomoses distales" avec plus de revascularisations tibiales dans le groupe traité. | Double aveugle Parallel groups Sample size: 122/121 Primary endpoint: occlusion à 24 mois FU duration: 24 mois La randomisation effectuée entre le 3ème et 14ème jour aprés l'intervention, sans stratification sur
centres.
Des déviations minimes au protocole ont été enregistrées pour 11 pts (6: gpe ttt, 5: placebo). |
|
| stable angina | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Berglund, 1985 | vs placebo | | | vascular death NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event NaN [NaN; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| Berglund, 1985 | ticlopidine 500 mg daily (n=21) vs. placebo (n=17) | middle-aged men with stable incapacitating angina pectoris | double blind parallel groups Sample size: 21/17 Primary endpoint: not defined FU duration: 2m |
|
| stent | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| FANTASTIC, 1998 | vs aspirin | | | MACE 0.70 [0.36; 1.36] | | ISAR, 1996 | vs aspirin | MACE 0.25 [0.09; 0.75] | | | | Foussas, 2000 | vs aspirin | MACE 0.31 [0.15; 0.63] | | | | MATTIS, 1998 | vs aspirin | | | MACE 0.51 [0.25; 1.07] | | STARS (vs coumadin+asp), 1998 | vs aspirin | MACE 0.20 [0.06; 0.69] | | | | STARS (vs aspirin), 1998 | vs aspirin | MACE 0.15 [0.05; 0.51] | | | | Hall, 1996 | vs aspirin | | | MACE 1.98 [0.24; 16.40] |
| Trial | Treatments | Patients | Method |
|---|
| FANTASTIC, 1998 | Ticlopidine 250 mg BID 6 wks Aspirin 100–325 mg qD (n=243) vs. Coumadin INR† 2.5–3.0 6 wks Aspirin 100–325 mg qD/pj (n=230) | | Sample size: 243/230 Primary endpoint: FU duration: | | ISAR, 1996 | Ticlopidine 250 mg BID 4 wks Aspirin 100 mg BIDage/pj (n=257) vs. Coumadin INR 3.5–4.5 4 wks Aspirin 100 mg BID (n=260) | | Sample size: 257/260 Primary endpoint: FU duration: | | Foussas, 2000 | Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD (n=203) vs. Coumadin INR 2–3 x4 wks Aspirin 325 mg qDg BID (n=201) | | Sample size: 203/201 Primary endpoint: FU duration: | | MATTIS, 1998 | Ticlopidine 250 mg BID 30 days Aspirin 250 mg qD (n=177) vs. Coumadin INR 2.5–3.0 x30 days Aspirin 250 mg qDg qD/pj (n=173) | | Sample size: 177/173 Primary endpoint: FU duration: | | STARS (vs coumadin+asp), 1998 | Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD (n=546) vs. Coumadin INR 2–2.5 x4 wks Aspirin 325 mg qDBID (n=550) | | Sample size: 546/550 Primary endpoint: FU duration: | | STARS (vs aspirin), 1998 | Ticlopidine 250 mg BID 4 wks Aspirin 325 mg qDDage/pj (n=546) vs. Aspirin 325 mg qD (n=557) | | Sample size: 546/557 Primary endpoint: FU duration: | | Hall, 1996 | Ticlopidine 250 mg BID 1 mo Aspirin 325 mg qD 5 days (n=13) vs. Aspirin 325 mg qD (n=103) | | Sample size: 13/103 Primary endpoint: FU duration: |
|
| thrombosis prevention | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| vs placebo | | | | | vs placebo | | | | | McKenna-II, 1983 | vs placebo | | | non PE related death NaN [NaN; NaN] major bleeding NaN [NaN; NaN] DVT 0.88 [0.53; 1.44] non fatal PE 0.67 [0.12; 3.70] wound haematoma / infection ∞ [NaN; ∞] fatal PE NaN [NaN; NaN] | | Lyon-II | vs placebo | | | non PE related death NaN [NaN; NaN] major bleeding NaN [NaN; NaN] DVT 0.62 [0.33; 1.15] non fatal PE ∞ [NaN; ∞] wound haematoma / infection 1.20 [0.44; 3.30] fatal PE NaN [NaN; NaN] | | Gardecki | vs placebo | | | non PE related death NaN [NaN; NaN] DVT 0.88 [0.72; 1.08] proximal DVT 1.12 [0.58; 2.16] non fatal PE 0.32 [0.03; 2.96] wound haematoma / infection 0.48 [0.04; 5.11] fatal PE NaN [NaN; NaN] | | McKenna-II , 1983 | vs placebo | | | Deep venous thrombosis 2.00 [0.49; 8.24] non fatal pulmonary embolism 0.00 [0.00; NaN] Fatal pulmonary embolism NaN [NaN; NaN] non pulmonary embolism death 0.00 [0.00; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| Lasierra, 1982 | Ticlopidine (n=40) vs. placebo (n=40) | | double-blind Sample size: 40/40 Primary endpoint: FU duration: | | Walker, 1974 | ticlopidine (n=31) vs. placebo (n=33) | | double-blind Sample size: 31/33 Primary endpoint: FU duration: | | McKenna-II, 1983 | Ticlopidine (n=29) vs. placebo (n=29) | Elective orthopaedic surgery | Sample size: 29/29 Primary endpoint: FU duration: 2 weeks | | Lyon-II | Ticlopidine (n=20) vs. placebo (n=20) | Elective orthopaedic surgery | Sample size: 20/20 Primary endpoint: FU duration: 3 weeks | | Gardecki | Ticlopidine (n=48) vs. placebo (n=46) | Elective orthopaedic surgery | Sample size: 48/46 Primary endpoint: FU duration: 2 weeks | | McKenna-II , 1983 | Ticlopidine (n=27) vs. placebo (n=26) | high risk (post CVA) medical patients | double-blind Parallel groups Sample size: 27/26 Primary endpoint: FU duration: |
|
